查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1597834

T 細胞治療市場：依方式、治療類型、適應症分類 - 全球預測 2025-2030

T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年T細胞治療市值為81.3億美元，預計2024年將達到98.5億美元，複合年成長率為21.23%，到2030年將達到313億美元。

T細胞療法是免疫療法的一個重要方面，利用基因工程T細胞來靶向並摧毀癌細胞，在現代癌症治療中顯示出巨大的潛力。需求在於能夠解決對傳統治療沒有反應的腫瘤並描述個人化治療方案。其應用和最終用途範圍從白血病和淋巴瘤等血癌到固體癌，包括醫院、研究機構和生物技術公司。推動市場成長的關鍵因素是CAR-T和TCR療法的進步、生物技術投資的增加以及癌症發生率的上升。然而，生產成本、複雜的監管環境和潛在的副作用是阻礙成長的顯著限制。最新的機會來自於 CRISPR 等基因編輯技術的進步，這些技術提高了 T 細胞的有效性，並將其擴展到自體免疫疾病等非腫瘤應用領域。為了利用這些機會，鼓勵生物技術公司和學術機構合作以簡化製造流程並降低成本。此外，可以透過專注於改善新型載體系統和遞送方法的安全性來解決監管挑戰和社會問題。儘管有這項承諾，市場仍面臨一些障礙，例如治療成本高、冷凍細胞運輸的物流以及需要大規模臨床測試以確保安全性和有效性。創新可能會在同種異體 T 細胞的開發等領域蓬勃發展，這可以減少製造時間和成本，以及使用次世代定序方法來提高目標識別的準確性並確保精準醫療。此外，人工智慧還可用於患者選擇和治療方法客製化，以實現最佳化的治療結果。隨著技術的快速進步，市場動態也高度動態，因此相關人員在不斷發展的研發領域保持敏捷以保持競爭力至關重要。

主要市場統計
基準年[2023] 81.3億美元
預測年份 [2024] 98.5億美元
預測年份 [2030] 313億美元
複合年成長率（%） 21.23%

市場動態：揭示快速發展的 T 細胞治療市場的關鍵市場洞察

T 細胞治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 隨著製造能力的擴大，核准增加
    • 癌症盛行率成長速度驚人
    • 獲得政府認可的適當報銷
  • 市場限制因素
    • CAR T 細胞免疫療法療效的限制以及 CAR T 細胞歸巢至腫瘤沉積物的不足
  • 市場機會
    • 免疫腫瘤學領域研發支出快速成長
    • 擴大基因和細胞療法的採用
  • 市場問題
    • 安全性問題和可能的副作用

波特五力：駕馭 T 細胞治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 T 細胞治療市場的外部影響

外部宏觀環境因素在塑造 T 細胞治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解T細胞治療市場的競爭格局

T 細胞治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣：T 細胞治療市場供應商的績效評估

FPNV定位矩陣是評估T細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製 T 細胞治療市場的成功之路

T 細胞治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著製造能力的擴大，核准增加
      • 癌症發生率成長速度驚人
      • 根據政府認可提供適當補償
    • 抑制因素
      • CAR-T細胞免疫療法療效的限制以及CAR-T細胞對腫瘤沉積物的歸巢不足
    • 機會
      • 免疫腫瘤學領域的研發經費快速增加
      • 擴大基因/細胞療法的引入
    • 任務
      • 安全性問題和可能的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 T 細胞治療市場：依方式分類

  • 介紹
  • 商業化
  • 研究

第7章 T 細胞治療市場：依治療類型

  • 介紹
  • CAR-T細胞療法
  • 基於T細胞受體
  • 基於腫瘤浸潤淋巴細胞

第8章 T 細胞治療市場：依適應症分類

  • 介紹
  • 造血系統惡性
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
  • 固態腫瘤
    • 大腦和中樞神經系統
    • 肝癌
    • 惡性黑色素瘤

第9章 美洲T細胞治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太T細胞治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲T細胞治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • DiaCarta, Inc.
  • Fate Therapeutics Inc.
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Poseida Therapeutics Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Tessa Therapeutics Pte. Ltd.
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market was valued at USD 8.13 billion in 2023, expected to reach USD 9.85 billion in 2024, and is projected to grow at a CAGR of 21.23%, to USD 31.30 billion by 2030.

T-cell therapy, a pivotal facet of immunotherapy, utilizes genetically modified T-cells to target and destroy cancer cells, presenting significant potential in modern oncology treatments. Its necessity lies in its ability to address tumors unresponsive to conventional therapies, offering personalized treatment options. The application and end-use scope range from blood cancers, such as leukemia and lymphoma, to solid tumors, spanning hospitals, research institutes, and biotech companies. Market growth is predominantly driven by advancements in CAR-T and TCR therapies, increased investment in biotechnology, and rising cancer prevalence. However, production cost, complex regulatory landscapes, and potential side effects serve as notable limitations hindering growth. The latest opportunities arise from advances in gene editing technologies like CRISPR, which could enhance T-cell efficacy, and expansion into non-oncological applications, such as autoimmune diseases. To capitalize on these opportunities, collaboration between biotech firms and academic institutions to streamline manufacturing processes and mitigate costs is recommended. Moreover, focusing on improving safety profiles through novel vector systems and delivery methods can address regulatory challenges and public concerns. Despite these prospects, the market faces hurdles in terms of high therapy costs, logistics of cryopreserved cell transport, and the need for extensive clinical trials to ensure safety and efficacy. Innovation can thrive in areas like developing allogeneic T-cells, which could reduce manufacturing time and cost, and harnessing next-generation sequencing methods for better target identification, ensuring precision medicine. Additionally, tapping into artificial intelligence for patient selection and therapy customization can yield optimized outcomes. The nature of the market is highly dynamic, with rapid technological progress, making it crucial for stakeholders to remain agile and responsive to evolving research and development fronts to maintain a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.85 billion
Forecast Year [2030] USD 31.30 billion
CAGR (%) 21.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Therapy Market

The T-Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing approvals along with expanding manufacturing capabilities
    • Alarming rate of increase in prevalence of cancers
    • Availability of adequate reimbursements with government awareness
  • Market Restraints
    • Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
  • Market Opportunities
    • Exponential R&D funding for immuno-oncology sector
    • Expanding adoption of gene and cell therapy
  • Market Challenges
    • Safety issues and possible side-effects

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Therapy Market

A detailed market share analysis in the T-Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Therapy Market

A strategic analysis of the T-Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Modality, market is studied across Commercialized and Research.
  • Based on Therapy Type, market is studied across CAR T-cell Therapy, T Cell Receptor-Based, and Tumor Infiltrating Lymphocytes-Based.
  • Based on Indication, market is studied across Hematologic Malignancies and Solid Tumors. The Hematologic Malignancies is further studied across Leukemia, Lymphoma, and Myeloma. The Solid Tumors is further studied across Brain & Central Nervous System, Liver Cancer, and Melanoma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
      • 5.1.1.2. Alarming rate of increase in prevalence of cancers
      • 5.1.1.3. Availability of adequate reimbursements with government awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
    • 5.1.3. Opportunities
      • 5.1.3.1. Exponential R&D funding for immuno-oncology sector
      • 5.1.3.2. Expanding adoption of gene and cell therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. T-Cell Therapy Market, by Modality

  • 6.1. Introduction
  • 6.2. Commercialized
  • 6.3. Research

7. T-Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. CAR T-cell Therapy
  • 7.3. T Cell Receptor-Based
  • 7.4. Tumor Infiltrating Lymphocytes-Based

8. T-Cell Therapy Market, by Indication

  • 8.1. Introduction
  • 8.2. Hematologic Malignancies
    • 8.2.1. Leukemia
    • 8.2.2. Lymphoma
    • 8.2.3. Myeloma
  • 8.3. Solid Tumors
    • 8.3.1. Brain & Central Nervous System
    • 8.3.2. Liver Cancer
    • 8.3.3. Melanoma

9. Americas T-Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific T-Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa T-Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Therapeutics PLC
  • 3. Amgen Inc.
  • 4. Bluebird Bio, Inc.
  • 5. Bristol Myers Squibb
  • 6. DiaCarta, Inc.
  • 7. Fate Therapeutics Inc.
  • 8. Gilead Sciences, Inc.
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Pfizer Inc.
  • 12. Poseida Therapeutics Inc.
  • 13. Sorrento Therapeutics, Inc.
  • 14. Takara Bio Inc.
  • 15. Tessa Therapeutics Pte. Ltd.

LIST OF FIGURES

  • FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. T-CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 234. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023